Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pulmonary Artery Catheters May Improve Heart Failure Quality Of Life

This article was originally published in The Gray Sheet

Executive Summary

Pulmonary artery catheterization (PAC) of severe heart failure patients is not associated with lower mortality, although it may assist doctors in improving patient quality of life, according to ESCAPE trial findings

You may also be interested in...

Pulmonary catheter study proposals to be reviewed by NHLBI advisory board Sept. 4.

PULMONARY ARTERY CATHETER RESEARCH PROPOSALS TO BE REVIEWED BY NHLBI advisory board on Sept. 4. The National Heart, Lung and Blood Institute's advisory panel is slated to review research proposals developed at an Aug. 25-26 workshop in Alexandria, Virginia sponsored by FDA and the National Institutes of Health to address questions about the safety and effectiveness of pulmonary artery catheters.

Jefferies' Survey Predicts M&A Rebound In 2021

An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies. 

Clinuvel’s Phototoxicity Drug Scenesse Approved In Third Market

Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts